This clinical trial is focused on improving recovery after minimally invasive colorectal surgery, which is a type of surgery performed on the colon or rectum using small incisions. The study will explore the effects of a treatment called Continuous Wound Infiltration, where a local pain relief medication, Bupivacaine, is continuously delivered to the surgical wound. This medication is a type of anesthetic that helps numb the area to reduce pain. The trial will compare the effects of this treatment to a placebo, which is a substance with no active medication, to see if it helps patients recover better after surgery.

The main goal of the study is to determine if using Bupivacaine in this way can improve the recovery process for patients who have undergone minimally invasive colorectal surgery. Participants in the study will receive either the Bupivacaine treatment or a placebo. The study will monitor their recovery over a period of time, focusing on how well they feel and how quickly they return to normal activities. The study will also track pain levels and the use of additional pain medications during the recovery period.

Throughout the study, participants will be asked to complete a daily questionnaire about their recovery, which will include questions about their pain levels and overall well-being. This information will help researchers understand the effectiveness of the treatment. The study will continue to collect data on participants’ recovery and any complications that may arise for up to 90 days after surgery. The findings from this study could provide valuable insights into improving post-surgical care for patients undergoing minimally invasive colorectal surgery.